Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2017

SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer

20170424 PR PHOCUS FPI EU – EN

Published 24 April 2017
Categorized as 2017, Pexa-Vec, Press release

Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors

20170419 TG Appointments Board EN

Published 19 April 2017
Categorized as 2017, Press release

Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial

20170412 PR Metro-JX Ph2 EN

Published 12 April 2017
Categorized as 2017, Pexa-Vec, Press release

Transgene Announces Upcoming Investor Meetings and R&D Day

20170410 PR Next investor events

Published 10 April 2017
Categorized as 2017, Press release

Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade

Laetitia Fend, et al.AACR, American Association for cancer Research, April 2017Download the poster herePoster Presentation

Published 5 April 2017
Categorized as -others, 2017, Publication, TG1050

In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC

Sandrine Cochin, et al. CLARA, Forum de la recherche en cancérologie, April 2017 Download the poster here Poster Presentation

Published 2 April 2017
Categorized as -others, 2017, Publication Tagged Oncolytic virus, Poster presentation

Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC

20170330-AACR poster EN

Published 30 March 2017
Categorized as 2017, Press release

Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017

20170320 2016 Resultats annuels EN

Published 20 March 2017
Categorized as 2017, Press release

First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

20170313 FPI Kelly study EN

Published 13 March 2017
Categorized as 2017, Press release, TG4010

Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine

Faleh Husseini, et al.Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the articlePublication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.

Published 22 February 2017
Categorized as 2017, Publication

Posts pagination

Newer posts Page 1 … Page 4 Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu